Rivaroxaban associated with increased bleeding risk compared with dabigatran in nonvalvular atrial fibrillation

2minutemedicine.com October 4, 2016

There was a total of 52 240 new starts of dabigatran and 66 651 new starts of rivaroxaban during the study period. Rivaroxaban was associated with a non-significant decrease in thromboembolic stroke. There was also a non-significant increase in mortality associated with rivaroxaban.

anticoagulation atrial fibrillation mortality risk stroke study

Fluid Personalization and Vasopressor Decisions in Early Sepsis Management

Fluid Personalization and Vasopressor Decisions in Early Sepsis Management

AKI Risk Factors in ICU Patients Using Colistin

AKI Risk Factors in ICU Patients Using Colistin

Clinical Outcomes in Critically Ill COVID-19 Unvaccinated Patients Admitted to the ICU

Clinical Outcomes in Critically Ill COVID-19 Unvaccinated Patients Admitted to the ICU

Haloperidol vs. Placebo in ICU Patients with Delirium

Haloperidol vs. Placebo in ICU Patients with Delirium

The High-risk Surgical Patient

Fleisher & Ludwig’s Textbook of Pediatric Emergency Medicine

Critical Care Nephrology and Renal Replacement Therapy in Children

Rapid Diagnosis of MRSA

Sepsis Management: PIRO and MODS

The Ventilator Book

Critical Care Administration: A Comprehensive Clinical Guide

Sepsis Management: PIRO and MODS

Extracorporeal Life Support for Adults

COVID-19 Airway Management and Ventilation Strategy for Critically Ill Older Patients

Critical Care: A New Nurse Faces Death, Life, and Everything in Between